BCR and chronic myelogenous leukemia, BCR-ABL1 positive: However, it has also been described that in most tumor models, NSC (CSC/LSC) cannot be eradicated completely using these drugs [11,24,28,130,204] as CSC/LSC often grow and survive independent of the primary (major) driver lesion, such as BCR/ABL in CML [204,205].